Riskpilot← Back to searchSign inGet full accessINCLINO AS
ASActiveOrg 983147011Hagaliveien 18, 1358 JarWholesale of pharmaceutical and medical goods · NACE 4646Est. 20011 employeeswww.inclino.no
Revenue 2025
NOK 7,3M
-40% vs 2024
EBITDA margin
18.9%
+1% vs 2024
Equity ratio
64.3%
Financial strength
Net profit 2025
NOK 1,2M
+12% vs 2024
| Revenue | NOK 7,3M | -40% |
| EBITDA | NOK 1,4M | +1% |
| Net profit | NOK 1,2M | +12% |
| Total assets | NOK 5,1M | -9% |
| Equity | NOK 3,3M | +6% |
| Employees | 1 | — |
Legal name
INCLINO AS
Org number
983147011
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21. mars 2001
Share capital
NOK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Konsulenttjenester for medisinsk utstyr, ved behov vil selskapet også drive med kjøp og salg av medisinsk utstyr.
Address
Hagaliveien 18, 1358 Jar
Website
www.inclino.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 9 456 | 10 581 | 11 680 | 12 260 | 7 300 |
| Staff expenses | −1 752 | −2 082 | −1 239 | −1 090 | −941 |
| EBITDA | 931 | 992 | 1 856 | 1 360 | 1 377 |
| Depreciation & amort. | −37 | −0 | −0 | −0 | −0 |
| EBIT | 894 | 992 | 1 856 | 1 360 | 1 377 |
| Net financials | −65 | −45 | 22 | 17 | 132 |
| Profit before tax | 829 | 946 | 1 878 | 1 376 | 1 509 |
| Tax | 183 | 210 | 414 | 305 | 311 |
| Net profit | 646 | 736 | 1 465 | 1 072 | 1 198 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 783 | 4 191 | 5 377 | 5 576 | 5 079 |
| Equity | 1 298 | 2 033 | 3 498 | 3 069 | 3 268 |
| Long-term debt | 701 | 730 | 317 | 0 | 0 |
| Short-term debt | 1 785 | 1 428 | 1 562 | 2 506 | 1 811 |
| Total debt | 2 485 | 2 158 | 1 879 | 2 506 | 1 811 |
EBITDA margin
18.9%
This company
15.8%
Market median
+20% vs market
20212025
Equity ratio
64.3%
This company
38.2%
Market median
+68% vs market
20212025
Return on equity
36.7%
This company
18.4%
Market median
+99% vs market
20212025
Net profit margin
16.4%
This company
8.1%
Market median
+102% vs market
20212025
Asset turnover
1.44×
This company
1.12×
Market median
+29% vs market
20212025
Debt / equity
0.55×
This company
0.62×
Market median
+11% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of INCLINO AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Asbjørn Bakken | Board of Directors | 0 companies |
| Martha Gjessing Bakken | Board of Directors | 0 companies |
| Petter Gjessing Bakken | Board of Directors | 0 companies |
| Edvard Bach Gjessing | Board of Directors | 0 companies |
| Nina Gjessing-Bakken | Chairman | 0 companies |
| Edvard Gjessing Bakken | Board of Directors | 0 companies |